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Objective: To investigate the effectiveness, safety, and tolerability of moxifloxacin (MXF) 
(intravenous [IV] or sequential therapy [IV followed by oral]) under daily treatment conditions 
in a large number of patients with respiratory tract infections.
Design: Patients with a diagnosis of respiratory tract infection should be treated with MXF IV 
and/or tablets 400 mg once daily for a duration at the physician’s discretion. For each patient, 
the physician documented data at an initial visit and at the end of therapy (EOT) visit and/or, in 
the case of sequential therapy, an interim visit when the patient switched to oral treatment.
Results: A total of 1953 patients treated with MXF were documented and were valid for an 
effectiveness and safety evaluation. An improvement was observed in 98.1% (n = 1911/1949) of 
patients treated with MXF. Recovery was documented in 89.9% (n = 1754/1951) of the patients. 
At the EOT visit, severity of infection was assessed to be “relieved” or at least “improved” 
in 96.5% (n = 1873/1940) of the patients. Physicians assessed overall effectiveness as “good” 
or “very good” in 93.3% (n = 1822/1953) of all patients. The physicians’ overall tolerability 
rating was “very good” or “good” in 93.5% (n = 1827/1953) of all patients. The incidence rates 
of adverse events (AEs) and adverse drug reactions (ADRs) were 0.72% (n = 14) and 0.67% 
(n = 13), respectively. One serious AE “falling white blood cell count” occurred (0.05%), which 
was also defined as a serious ADR and resolved.
Conclusion: MXF was generally well tolerated and highly effective in the treatment of different 
respiratory tract infections. The incidence of AEs and ADRs was low. The efficacy, safety, and 
tolerability information collected in this study confirms the clinical safety profile of MXF and 
its value as antibiotic treatment for respiratory tract infections.
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Introduction
Respiratory tract infections, such as community-acquired pneumonia (CAP), acute 
exacerbation of chronic bronchitis (AECB), or acute bacterial sinusitis, are important 
causes of morbidity and mortality worldwide. The most frequent causative organism 
in CAP is Streptococcus pneumoniae or, less commonly, one of the atypical organisms 
Mycoplasma pneumoniae, Chlamydophila pneumonia, or Legionella pneumophilia.1 
In AECB, the primary organisms are Haemophilus influenzae, S. pneumonia, and 
Moraxella catarrhalis.2
The antibiotic used to treat any of these respiratory tract infections should be chosen 
to maximize bacterial eradication and minimize the risk of antimicrobial resistance 
development. Of particular concern is the emergence of the multidrug-resistant 
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Moxifloxacin is an 8-metoxifluoroquinolone with a broad 
spectrum of antibacterial activity. It is effective against 
Gram-positive pathogens and Gram-negative pathogens, 
atypical pathogens, and anaerobic bacteria. Among 
respiratory pathogens, most penicillin- and macrolide-
resistant and β-lactamase-producing strains are sensitive to 
moxifloxacin.5
This study was designed to obtain data on the effective-
ness and safety of moxifloxacin (administered intravenously 
[IV] or sequentially [IV followed by oral]) under daily treat-
ment conditions in China in a large number of patients with 
diagnosed bacterial respiratory tract infections.
Materials and methods
study design
This was a prospective, noninterventional, noncontrolled, 
multicenter, postmarketing surveillance trial conducted 
between February 2006 and March 2007 in China in 
patients presenting at a hospital as part of a global study. 
The study was carried out within an approved indication 
in accordance with US Food and Drug Administration and 
European Medicines Agency guidelines and applicable 
local law(s) and regulation(s). Only data and observations 
surveyed during regular therapy with moxifloxacin were 
documented. No intervention in the therapeutic decisions 
of the investigator was allowed. Doctors were instructed to 
prescribe moxifloxacin for treatment of a respiratory tract 
infection in the usual manner in accordance with the Chinese 
marketing authorization as far as possible. No additional 
diagnostic or monitoring procedures were applied to patients. 
For each patient, the physician documented data at an initial 
visit and an end of therapy (EOT) visit and/or, in the case of 
sequential therapy, an interim visit when the patient switched 
to oral treatment. Observation parameters were fever, cough, 
dyspnea, and sputum, which were documented to assess 
symptom development. Effectiveness parameters included 
course of severity of infection, course of patient’s general 
condition, course of clinical signs and symptoms, duration 
until improvement and recovery, and overall assessment of 
effectiveness by patient and physician. Safety parameters 
were adverse events (AEs), including adverse drug reactions 
(ADRs), and global assessment of tolerability.
Data analysis
Descriptive and explorative analyses were conducted with 
the software system SAS® for Windows, (Version 9.1; SAS 
Institute, Lans, NC) According to confidentiality guidelines, 
each patient was assigned an individual five-digit number 
(pseudonymization), and only the physicians knew which 
patient had which number and could identify the patient. The 
analysis was based on the intent-to-treat (ITT) population. 
For qualitative variables, absolute and relative frequencies 
were calculated. For stratified analyses, row percents (row%) 
and column percents (col%) were calculated. For numeric 
data, the following distribution parameters were calculated: 
median, mean, standard deviation (SD), minimum, maxi-
mum, and 1%, 5%, 25%, 75%, 95%, and 99% percentiles. 
For coding of verbatim documentation, the following coding 
systems were applied: concomitant therapies: World Health 
Organization DD 2005/Q3; adverse events: MedDRA® Ver-
sion 10.0.
study population
ITT population/safety population
The definitions for the safety and the ITT populations were 
identical in this study. Patients were included in the ITT 
population if at least one dose of moxifloxacin was taken 
during the observational period. Seventy-four of 2027 
enrolled patients were excluded from ITT analysis due to 
one or more of the following reasons: i) patient double entry, 
ii) first visit in more than 2 days before the start of the study 
(retrospective documentation), and iii) no symptoms at initial 
visit. Thus, for the ITT population as well as in the safety 
analysis, data of 1953 patients were analyzed.
Results
Demographics
A total of 1953 patients treated with moxifloxacin were 
documented and were valid for effectiveness and safety 
evaluation. The vast majority of patients were of Asian origin 
(99.8%); one patient was white (0.1%) and one patient was 
black (0.1%). For two patients, information on race was 
missing (0.1%). A total of 1284 patients were male (65.7%), 
and 669 patients were female (34.3%). The age ranged from 
14.0 to 105.0 years with a mean age of 59.6 ± 17.5 years. 
A total of 46.9% (n = 915/1953) of the patients suffered from 
CAP, and 40.1% (n = 783/1953) of the patients examined 
were diagnosed with AECB. Combined infections (CAP and 
AECB, CAP and other, AECB and other, CAP and AECB 
and other) were diagnosed in 3.8% (n = 75/1953) of all cases, 
and 15.9% (n = 310/1953) of patients were affected by other 
infections. Most frequent “other infections” were respiratory 
infection (7.4%, n = 23/310), cross-infection in hospital (4.8%, 
n = 15/310), and inhalation pneumonia (4.8%, n = 15/310). Of 
the patients, 22.4% were smokers and 19.3% past smokers, 
which is known to be an important etiological factor with International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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regard to chronic bronchitis; 57.5% of the patients were 
nonsmokers. In terms of alcohol consumption, the majority 
of patients were abstinent (81.0%). The current infection was 
rated by the attending physicians to be “mild” in 205 patients 
(10.5%), “moderate” in 1217 patients (62.3%), and “severe’” 
in 518 (26.5%) of the patients. A total of 721 (36.9%) patients 
(38.2% of AECB patients and 30.7% of the CAP group) 
had already received at least one antibiotic treatment for the 
current bacterial infection before the start of moxifloxacin 
therapy, whereas the majority of 1186 patients (60.7%) had 
not yet received any antibiotic pretreatment (Table 1).
Treatments
The route of moxifloxacin application was exclusively IV in 
78.3% of patients, whereas moxifloxacin sequential therapy 
was administered in 21.6% of the patients. In the case of 
sequential therapy, 415 out of 421 patients (98.6%) started 
with moxifloxacin IV therapy and then switched to oral 
treatment. A minority of six patients (1.4%) changed from 
oral to IV treatment. A total of 99.6% of all patients treated 
with IV (patients treated exclusively with IV and treated by 
sequential therapy) received the recommended daily dose 
of 400 mg, six patients (0.3%) were administered 800 mg 
moxifloxacin treatment, and in one case (0.1%) information 
on moxifloxacin IV dose was missing. Oral therapy was 
administered as a 400 mg daily dose regimen in 99.8% of 
the patients, and in only one case (0.1%) was information 
missing.
The mean duration of moxifloxacin treatment was 9.1 days 
(SD 3.6 days) with a median of 8.0 days. Sequential therapy 
lasted, on average, 12.5 days (SD 3.8 days). Exclusive IV 
therapy was applied for, on average, 8.1 days (SD 2.9 days).
The total treatment duration varied with the patients’ 
diagnoses: AECB therapy was slightly shorter (8.9 days, 
SD 3.7 days) compared with CAP therapy (9.2 days, SD 
3.4 days) and the therapy for other diagnoses (9.0 days, SD 
3.7 days), respectively. Combined infections were treated 
for an average of 8.4 days (SD 2.8 days). The majority of all 
documented patients treated by sequential therapy (53.2%, 
224/421) received moxifloxacin treatment for a time period 
of 10–14 days, whereas duration for most patients treated 
exclusively with IV therapy was 7–9 days (41.2%, 631/1530). 
A small proportion of patients was treated for less than 5 days 
(sequential therapy: 0.5%; IV therapy: 2.8%). A total of 26.8% 
treated by sequential therapy and 3.3% treated by exclusive IV 
therapy, respectively, were treated for more than 14 days.
effectiveness results
At each visit, the patients’ condition and severity of infection 
were assessed and recorded by the attending physician. 
Additionally, fever and the three most prevalent symptoms 
(dyspnea, cough, and sputum) were reported (Figure 1). The 
patients’ condition and severity of infection at the start and 
end of therapy are displayed in Figures 2 and 3.
In total, there were 1949 patients recorded with data 
on improvement and 1951 patients recorded with data on 
recovery. A total of 82.5% (n = 1607/1949) of the patients had 
improved after 5 days of treatment; 68.9% (n = 1345/1951) 
patients recovered after 10 days. At the end of the obser-
vational period, an improvement was observed in 98.1% 
(n = 1911/1949) of the respiratory tract infection patients 
treated with moxifloxacin, and recovery was documented 
for 89.9% (n = 1754/1951) of the participating patients 
(Figure 4).
Moxifloxacin IV treatment, as well as sequential therapy 
(moxifloxacin IV/oral), was very effective in the treatment of 
respiratory tract infections. For 93.3% (n = 1822/1953) of the 
Table 1 Baseline demographics and diagnosis
Demographic Patients (n = 1953)
Sex
Male 1284 (65.7%)
Female 669 (34.3%)
Age (years)
,65 1038 (53.1%)
$65 866 (44.3%)
Missing 49 (2.5%)
Diagnosis
Community-acquired pneumonia 915 (46.9%)
Acute exacerbation of chronic bronchitis 783 (40.1%)
Other infection 310 (15.9%)
Combined infection 75 (3.8%)
Nicotine consumption
Missing 18 (0.9%)
nonsmoker 1122 (57.5%)
Current smoker 437 (22.4%)
Past smoker 376 (19.3%)
Alcohol consumption
Missing 17 (0.9%)
Abstinent 1581 (81.0%)
Light 235 (12.0%)
Moderate 89 (4.6%)
heavy 31 (1.6%)
Severity
no infection 4 (0.2%)
Mild 205 (10.5%)
Moderate 1217 (62.3%)
severe 518 (26.5%)
Antibiotic pretreatment
Missing 46 (2.4%)
no 1186 (60.7%)
Yes 721 (36.9%)International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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Figure 1 Course of severity of fever, dyspnea, and cough from first to last visit.
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Figure 2 Course of patients’ condition from first to last day of therapy.
documented patients, effectiveness was rated as “very good” 
(56.4%, n = 1102/1953) and “good” (36.9%, n = 720/1953) 
by the attending physician. For “sufficient” and “insufficient”, 
5.3% (n = 103/1953) and 1.3% (n = 25/1953) were rated 
individually. The overall effectiveness assessment made by 
the physicians is shown in Figure 5. Stratification by diagnosis 
revealed best ratings (“very good” and “good”) in the patient 
group suffering from CAP (94.5%). Of the AECB patients, 
92.6% had “very good” and “good” effectiveness ratings, 
compared with 88.1% of patients with other infections. The 
physicians’ final assessment of effectiveness was also strati-
fied by severity of the infection at the initial visit: Effective-
ness was assessed as “very good” and “good” in 95.1% of 
patients with a “mild” infection, in 94.6% of patients with a 
“moderate” infection, and in 89.8% of patients with a “severe” 
infection. In multimorbid patients with at least two concomi-
tant diseases, effectiveness was assessed as “very good” and 
“good” in 91.3% of patients compared with 95.0% of patients 
with fewer than two concomitant diseases.
Physicians recorded that 96.8% (n = 1890/1953) of 
patients were “very satisfied” (58.2%, n = 1137/1953) or 
“satisfied” (38.6%, n = 753/1953) with the therapeutic effect 
of moxifloxacin. “Not satisfied” was rated in only 2.9% 
(n = 56/1953) of patients.
safety and tolerability
During this open-label moxifloxacin postmarketing surveil-
lance study of 1953 patients in China, moxifloxacin was 
principally well tolerated. The physicians’ overall tolerability 
rating was “very good” (57.1%, n = 1115/1953) or “good” 
(36.5%, n = 712/1953) in 93.5% (n = 1827/1953) of all 
patients. The physicians rated tolerability as “sufficient” in 
5.1% and as “insufficient” in 0.8% of the patients individually 
(Figure 6).International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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Figure 4 Duration until improvement and recovery after first administration of moxifloxacin.
Pretreatment (95.6% “very good” or “good”) as well 
as lower morbidity (fewer than two concomitant diseases, 
94.4% “very good” or “good”) revealed better results 
regarding tolerability compared with patients without 
pretreatment (90.6% “very good” or “good”) and patients 
with higher morbidity (two or more concomitant diseases, 
92.5%).
The incidence rates of AEs and ADRs were 0.72% 
(n = 14/1953) and 0.67% (n = 13/1953), respectively. 
Symptoms such as nausea and vomiting, which are well 
known in antibiotic treatment and also with quinolones, were 
predominant (each with 0.15%). One serious AE occurred 
(0.05%), which was also defined as a serious ADR. In this 
case, an 82-year-old male patient encountered “falling white 
blood cell count”, which led to “hospitalization necessary or 
prolonged”, but the event finally resolved.
In total, there were 33 AEs. Out of those, 29 were 
  considered ADRs. Twenty-eight of the AEs (24 of 29 ADRs) 
were resolved or improved by the end of the observational 
period. In other cases, information on event outcome was 
missing. Table 2 summarizes AEs and ADRs.
Discussion
Infections occur in the respiratory tract more frequently than 
in any other site. Acute respiratory tract infections are the 
most common illnesses in humans and are associated with 
significant morbidity and mortality. Antibiotics are com-
monly prescribed empirically for respiratory tract infections 
in adults and children in primary care.
The inappropriate prescribing of antibiotics has the 
potential to cause drug-related AEs, escalate the preva-
lence of antibiotic-resistant organisms in the community, 
and increase primary care consultation rates for minor 
illness (Standing Medical Advisory Committee 1998). 
How to use antibiotics in the treatment of respiratory tract 
infection appropriately is a big challenge for prescribers. 
Fortunately, there are national and international guidelines 
for the treatment of respiratory tract infections, eg, the International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
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European Respiratory Society’s lower respiratory tract 
infections guidelines.6 In China, guidelines were also 
established to guarantee the appropriate use of antibiotics 
in respiratory tract infection patients, especially CAP 
and AECB patients. Moxifloxacin is recommended in 
both Chinese guidelines7,8 for treating CAP and AECB. 
For CAP, moxifloxacin is recommended for preliminary 
empirical use in the following patients: young to middle-
aged adults without underlying disease, elderly people 
or those with underlying disease, patients who have been 
hospitalized but not admitted to the intensive care unit 
(ICU), those using a combination with other antibacteri-
als in ICU for Pseudomonas aeruginosa infection risk, 
and those with aspiration factor. For AECB, moxifloxacin 
is recommended for empirical use in Grade III and IV 
patients without P . aeruginosa infection risk. More and 
more physicians have experience in using moxifloxacin in 
China; nevertheless, there is still the need to collect and 
analyze local data, especially with a large sample size in 
clinical practice, in order to gather the newest efficacy 
data in treatment with moxifloxacin.
In our study, 2027 subjects were enrolled and 1953 
were included in the statistical analysis. The mean age of 
all patients was 59.6 years (SD 17.5 years). A patient age over 
45 years should be considered a major factor for defining the 
presence of chronic bronchitis. Indeed, AECB patients were 
more frequently older patients (80.8% of them were aged 
50 years and older), whereas CAP patients were nearly evenly 
distributed in the age range of 30–79 years.
The overall effectiveness assessment showed that for 1822 
(93.3%) of 1953 documented patients, effectiveness was 
rated as “very good” and “good” by the attending physician. 
Liu and Landen reported in 2007 that in their postmarketing 
surveillance of moxifloxacin in treating respiratory tract 
infection, improvement was observed in 69.1% of the patients 
after 3 days of moxifloxacin treatment and in 90.4% after 
5 days.9 Full recovery had occurred in 71.3% by 7 days 
and in 86.8% by 10 days. Physicians rated moxifloxacin as 
“very good” or “good” in 92% of patients for effectiveness. 
The results are similar in both studies, which demonstrated 
moxifloxacin to be of good effectiveness in treating respira-
tory tract infection.9
For safety consideration, moxifloxacin treatment was 
well tolerated, with physicians rating overall tolerability as 
“very good” and “good” in 93.5% of patients. The physi-
cians rated tolerability to be “sufficient” in 5.1% and to be 
“insufficient” in 0.8% of the patients. Pretreatment (95.6%) 
as well as lower morbidity (fewer than two concomitant 
diseases, 94.4%) corresponded to better results regarding 
tolerability compared with “no” pretreatment (90.6%) and 
higher morbidity (two or more concomitant diseases, 92.5%). 
The incidence rates of AEs and ADRs were 0.72% and 0.67%, 
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Figure 6 Physicians’ final assessment of tolerability.
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Table 2 Incidence of adverse events (Aes) and adverse drug 
reactions (ADrs) by MedDrA system organ classes and preferred 
terms
System organ classes  
and preferred terms
Patients (n = 1953)
AE ADR
n (%) n (%)
Patients with Ae/ADr 14 (0.72) 13 (0.67)
Patients without Ae/ADr 1939 (99.28) 1940 (99.33)
Gastrointestinal disorders 3 (0.15) 3 (0.15)
General disorders and  
administration site conditions
2 (0.10) 1 (0.05)
hepatobiliary disorders 1 (0.05) 1 (0.05)
Investigations 2 (0.10) 2 (0.10)
Metabolism and nutrition disorders 3 (0.15) 2 (0.10)
nervous system disorders 2 (0.10) 1 (0.05)
Psychiatric disorders 3 (0.15) 3 (0.15)
skin and subcutaneous tissue disorders 4 (0.20) 4 (0.20)
Vascular disorders 2 (0.10) 2 (0.10)International Journal of General Medicine
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respectively. Symptoms such as nausea and vomiting, which 
are well known in antibiotic treatment, were predominant 
(0.15%, respectively). These low numbers underline the very 
good tolerability and safety of moxifloxacin. Similar results 
were acquired from Liu and Landen’s study.9 Physicians 
rated moxifloxacin as “very good” or “good” in 90.8% of the 
patients for tolerability. A total of 129 AEs occurred in 74 
(1.9%) patients and mainly involved either the gastrointesti-
nal or nervous system. All events were mild or moderate, and 
most resolved or improved after stopping treatment.9
This study involved 150 investigators and enrolled a 
large number of patients in China. The results are help-
ful for physicians in clinical practice for treating AECB. 
Although this study lacked bacteriological testing and 
did not evaluate bacterial outcome, in medical practice, 
antibiotics are evaluated on the basis of clinical signs and 
symptoms. Nevertheless, this study is a single-arm, open-
label study, and bias is inevitable when evaluating final 
effectiveness. Stricter studies in clinical practice are needed 
to further investigate this area. In general, the data of this 
study provide a large sample of evidence from China for 
rational antibiotic usage in treating respiratory tract infec-
tions in the future.
Conclusion
In this observational study, moxifloxacin was generally well 
tolerated and highly effective in the treatment of different 
respiratory tract infections requiring initial IV therapy. 
The incidence of AEs and ADRs was low. The safety and 
tolerability information collected in this study confirms the 
clinical safety profile of moxifloxacin and its benefit as a 
valuable choice of antibiotic treatment for respiratory tract 
infections.
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